Huvos AG, Lucas JC Jr, Foote FW Jr. Metaplastic breast carcinoma. Rare form of mammary cancer. N Y State J Med. 1973;73(9):1078–82.

CAS  Google Scholar 

Weigelt B, Eberle C, Cowell CF, Ng CK, Reis-Filho JS. Metaplastic breast carcinoma: more than a special type. Nat Rev Cancer. 2014;14(3):147–8. https://doi.org/10.1038/nrc3637.

Article  CAS  Google Scholar 

Reddy TP, Rosato RR, Li X, Moulder S, Piwnica-Worms H, Chang JC. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 2020;22(1):121. https://doi.org/10.1186/s13058-020-01353-z.

Article  Google Scholar 

Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the National Cancer Data Base (NCDB). Ann Surg. 2018;268(4):591–601. https://doi.org/10.1097/sla.0000000000002953.

Article  Google Scholar 

Schroeder MC, Rastogi P, Geyer CE Jr, Miller LD, Thomas A. Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in surveillance, epidemiology, and end results (SEER) 2010–2014. Oncologist. 2018;23(4):481–8. https://doi.org/10.1634/theoncologist.2017-0398.

Article  CAS  Google Scholar 

Chen IC, Lin CH, Huang CS, et al. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011;130(1):345–51. https://doi.org/10.1007/s10549-011-1686-9.

Article  CAS  Google Scholar 

Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14(1):166–73. https://doi.org/10.1245/s10434-006-9124-7.

Article  Google Scholar 

Nelson RA, Guye ML, Luu T, Lai LL. Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol. 2015;22(1):24–31. https://doi.org/10.1245/s10434-014-3890-4.

Article  Google Scholar 

Aydiner A, Sen F, Tambas M, et al. Metaplastic breast carcinoma versus triple-negative breast cancer: survival and response to treatment. Medicine (Baltimore). 2015;94(52):e2341. https://doi.org/10.1097/md.0000000000002341.

Article  CAS  Google Scholar 

Thapa B, Arobelidze S, Clark BA, et al. Metaplastic breast cancer: characteristics and survival outcomes. Cureus. 2022;14(8):e28551. https://doi.org/10.7759/cureus.28551.

Article  Google Scholar 

Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(5):331–7. https://doi.org/10.6004/jnccn.2024.0035.

Article  CAS  Google Scholar 

Riedel F, Hoffmann AS, Moderow M, et al. Time trends of neoadjuvant chemotherapy for early breast cancer. Int J Cancer. 2020;147(11):3049–58. https://doi.org/10.1002/ijc.33122.

Article  CAS  Google Scholar 

Rogers C, Cobb AN, Lloren JIC, et al. National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial. Breast Cancer Res Treat. 2024;203(2):317–28. https://doi.org/10.1007/s10549-023-07114-8.

Article  CAS  Google Scholar 

Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23:x231-6. https://doi.org/10.1093/annonc/mds324.

Article  Google Scholar 

De Luca A, Amabile MI, Santori F, et al. Neoadjuvant chemotherapy for breast cancer in Italy: a senonetwork analysis of 37,215 patients treated from 2017 to 2022. Breast. 2024. https://doi.org/10.1016/j.breast.2024.103790.

Article  Google Scholar 

Huang M, O’Shaughnessy J, Zhao J, et al. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res. 2020;80(24):5427–34. https://doi.org/10.1158/0008-5472.Can-20-1792.

Article  CAS  Google Scholar 

Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–48. https://doi.org/10.1158/1078-0432.Ccr-19-3492.

Article  Google Scholar 

Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. https://doi.org/10.1016/s0140-6736(13)62422-8.

Article  Google Scholar 

Haque W, Verma V, Schwartz MR, et al. Neoadjuvant chemotherapy for metaplastic breast cancer: response rates, management, and outcomes. Clin Breast Cancer. 2022;22(5):e691–9. https://doi.org/10.1016/j.clbc.2022.01.006.

Article  CAS  Google Scholar 

Al-Hilli Z, Choong G, Keeney MG, et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019;176(3):709–16. https://doi.org/10.1007/s10549-019-05264-2.

Article  CAS  Google Scholar 

Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13–21. https://doi.org/10.1200/jco.2014.57.0572.

Article  CAS  Google Scholar 

Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33(5):534–43. https://doi.org/10.1016/j.annonc.2022.02.004.

Article  CAS  Google Scholar 

Hennessy BT, Giordano S, Broglio K, et al. Biphasic metaplastic sarcomatoid carcinoma of the breast. Ann Oncol. 2006;17(4):605–13. https://doi.org/10.1093/annonc/mdl006.

Article  CAS  Google Scholar 

Wong W, Brogi E, Reis-Filho JS, et al. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer. 2021;7(1):96. https://doi.org/10.1038/s41523-021-00302-z.

Article  CAS  Google Scholar 

Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM. Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clin Oncol. 2017;29(10):642–52. https://doi.org/10.1016/j.clon.2017.06.003.

Article  CAS  Google Scholar 

Yoen H, Kim SY, Lee DW, Lee HB, Cho N. Prediction of tumor progression during neoadjuvant chemotherapy and survival outcome in patients with triple-negative breast cancer. Korean J Radiol. 2023;24(7):626–39. https://doi.org/10.3348/kjr.2022.0974.

Article  Google Scholar 

Tadros AB, Sevilimedu V, Giri DD, Zabor EC, Morrow M, Plitas G. Survival outcomes for metaplastic breast cancer differ by histologic subtype. Ann Surg Oncol. 2021;28(8):4245–53. https://doi.org/10.1245/s10434-020-09430-5.

Article  Google Scholar 

Han M, Salamat A, Zhu L, et al. Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. Mod Pathol. 2019;32(6):807–16. https://doi.org/10.1038/s41379-019-0208-x.

Article  Google Scholar 

Yam C, Abuhadra N, Sun R, et al. Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res. 2022;28(13):2878–89. https://doi.org/10.1158/1078-0432.Ccr-21-3100.

Article  CAS  Google Scholar 

Drekolias D, Mamounas EP. Metaplastic breast carcinoma: current therapeutic approaches and novel targeted therapies. Breast J. 2019;25(6):1192–7. https://doi.org/10.1111/tbj.13416.

Article  Google Scholar 

Ong CT, Campbell BM, Thomas SM, et al. Metaplastic breast cancer treatment and outcomes in 2500 patients: a retrospective analysis of a national oncology database. Ann Surg Oncol. 2018;25(8):2249–60. https://doi.org/10.1245/s10434-018-6533-3.

Article  Google Scholar 

de Boniface J, Szulkin R, Johansson ALV. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48 986 women. JAMA Surg. 2021;156(7):628–37. https://doi.org/10.1001/jamasurg.2021.1438.

Article  Google Scholar 

Corso G, Frassoni S, Girardi A, et al. Metaplastic breast cancer: Prognostic and therapeutic considerations. J Surg Oncol. 2021;123(1):61–70. https://doi.org/10.1002/jso.26248.

Article  CAS  Google Scholar 

Ismail Y, Kamal A, Allam R, Zakaria AS. The conundrum of metaplastic breast cancer: a single Egyptian institution retrospective 10-year experience (2011–2020). J Egypt Natl Canc Inst. 2023;35(1):16. https://doi.org/10.1186/s43046-023-00178-z.

Article  Google Scholar 

Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59. https://doi.org/10.1056/NEJMoa1612645.